Back to Search Start Over

In vivo therapeutic applications of phosphorus dendrimers: state of the art

Authors :
Jean-Pierre Majoral
Serge Mignani
Maria Bryszewska
Xiangyang Shi
Dzmitry Shcharbin
Valentín Ceña
Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques (LCBPT - UMR 8601)
Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)
Centro de Química da Madeira
Universidade da Madeira (UMA)
State Key Laboratory for Fiber & Material Modification of Donghua University
Donghua University [Shanghai]
Centro de Investigacion Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)
Instituto de Salud Carlos III [Madrid] (ISC)
Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz
University of Lódź
Laboratoire de chimie de coordination (LCC)
Institut de Chimie de Toulouse (ICT)
Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3)
Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP)
Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3)
Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)
PRC NSFC-CNRS 2019 (21911530230
199675)
FCT-Fundação para a Ciência e a Tecnologia (Base Fund UIDB/00674/2020 and Programmatic Fund UIDP/00674/2020, Portuguese Government Funds)
ARDITI-Agência Regional para o Desenvolvimento da Investigação Tecnologia e Inovação through the project M1420-01-0145-FEDER-000005-CQM+ (Madeira 14-20 Program)
EuroNanoMed III (ERANET)
Spanish Ministerio de Economía y Competitividad (project SAF2017-89288-R from MINECO/AEI/FEDER/UE) (project SBPLY/19/180501/000067)
CNRS
Polish National Agency for Academic Exchange (grant EUROPARTNER, No. PPI/APM/2018/1/00007/U/001)
Belarusian Republican Foundation for Fundamental Research and State Committee of Science and Technology of Belarus (grants B19ARMG-002 and B20SLKG-002)
Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)
Institut National Polytechnique (Toulouse) (Toulouse INP)
Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse III - Paul Sabatier (UT3)
Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599)
Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3)
Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)
Source :
Drug Discovery Today, Drug Discovery Today, 2021, 26 (3), pp.677-689. ⟨10.1016/j.drudis.2020.11.034⟩, Drug Discovery Today, Elsevier, 2021, 26 (3), pp.677-689. ⟨10.1016/j.drudis.2020.11.034⟩
Publication Year :
2021
Publisher :
HAL CCSD, 2021.

Abstract

International audience; Among the different types of dendrimers, those that incorporate phosphorus in various positions in their structures present fascinating properties and have wide applications in pharmaceutical fields such as drug delivery (including gene transfection), diagnosis and imaging. Therapeutic agents can be encapsulated within the dendritic architecture, or chemically attached or physically adsorbed onto the dendrimer surface. Alternatively, phosphorus dendrimers can be developed as drugs themselves, for instance to treat cancer, inflammations, infections and neurodegenerative diseases, although there are fewer examples of this second approach. Here, we review the most relevant in vivo biological activities of phosphorus dendrimers (whether as active drugs per se or as nanocarriers) across various therapeutic domains, including anti-inflammation, transmissible spongiform encephalopathies, ocular hypertension, infection, gene therapy, ultrasound-targeted microbubble destruction and two-photon in vivo imaging. We discuss the success of phosphorus dendrimers in nanomedicine and look ahead to future innovations in the field.

Details

Language :
English
ISSN :
13596446
Database :
OpenAIRE
Journal :
Drug Discovery Today, Drug Discovery Today, 2021, 26 (3), pp.677-689. ⟨10.1016/j.drudis.2020.11.034⟩, Drug Discovery Today, Elsevier, 2021, 26 (3), pp.677-689. ⟨10.1016/j.drudis.2020.11.034⟩
Accession number :
edsair.doi.dedup.....34b448585ee7d8be4da3514afbf5eae1